NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD) | MicrobiomeTrials← Back to trialsNCT05189925
NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2022-07-22Est. Completion: 2027-07-01
Enrollment target: 25 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Chronic Granulomatous Disease (CGD)
Background:
X-Linked Chronic Granulomatous Disease (X-CGD) is caused by a gene mutation that makes the immune system to…
Bethesda, United StatesCompleted Sep 1, 2028
GranulomaGranulomatous Disease, ChronicLeukocyte DiseaseGenetic Disease, X-LinkedGenetic Disease, Inborn
The research goal of this study is to obtain CD34+ hematopoietic stem cells (HSC) from peripheral blood and/or bone marr…
Bethesda, United States